Advancements in In Vivo CAR-T Cell Therapy Using CRISPR-Cas9

Recent research published in *Nature* highlights the potential of the CRISPR-Cas9 gene-editing system to revolutionize chimeric antigen receptor (CAR)-T-cell therapies by enabling the engineering of cancer-fighting immune cells directly within the human body. This innovative approach could lead to safer, more effective treatments for blood cancers, such as leukemia and lymphoma, while also reducing costs and the need for toxic pre-treatment regimens.

Nature

Traditional CAR-T therapies involve extracting a patient’s T cells, modifying them to express a synthetic protein known as a CAR, and reinfusing them into the patient. This process is labor-intensive and costly, often requiring chemotherapy to eliminate unaltered immune cells, which leaves patients vulnerable to infections. The new research aims to streamline this process by allowing T cells to be engineered in vivo, potentially creating a universal therapy applicable to multiple patients.

Nature

The study, led by Justin Eyquem, an immunologist at the University of California, San Francisco, represents a significant step toward making in vivo CAR-T-cell treatments a reality. Eyquem and his team previously demonstrated the feasibility of using CRISPR-Cas9 to enhance CAR T cell effectiveness in isolated T cells, paving the way for this new approach.

Nature

The ability to engineer T cells directly in the body could transform cancer treatment by eliminating the need for costly and time-consuming procedures. This method promises to make CAR-T therapies more accessible and less burdensome for patients, potentially leading to improved outcomes in cancer care.

Nature

Despite the promising advancements, safety concerns remain paramount. Eyquem emphasizes the importance of ensuring that the CRISPR-Cas9 system targets only T cells and does not inadvertently edit other cell types, which could lead to harmful mutations. The research team has incorporated multiple safety layers to mitigate these risks, but the potential for random insertion of synthetic genes into the T-cell genome raises questions about the possibility of cancer-causing mutations.

Nature

While the research has made significant strides, critics point out that the safety of in vivo CAR-T-cell therapies is still under scrutiny. Concerns about the random insertion of genes and the risk of unintended consequences highlight the need for rigorous testing and oversight as these therapies move into clinical trials.

Nature

The first in vivo CAR-T-cell treatments are currently in early clinical trials, marking a critical phase in the development of this innovative therapy. As researchers continue to address safety concerns and refine the technology, the potential for CRISPR-Cas9 to reshape cancer treatment remains a focal point in the medical community.

Nature

“It sounded like science fiction.” — Justin Eyquem, Immunologist, University of California, San Francisco

Nature

“you don’t want to edit other cells” — Justin Eyquem, Immunologist, University of California, San Francisco

Nature

“ Since then, researchers have taken steps towards making in vivo CAR-T-cell treatments a reality.” — Justin Eyquem, Immunologist, University of California, San Francisco

Nature